Related Experiment Video
Updated: Sep 6, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe
Stanisław Malicki1,2, Barbara Pucelik1, Edyta Żyła1
1Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7a, 30-387 Krakow, Poland.
Abstract:
Immune checkpoint targeting immunotherapy has revolutionized the treatment of certain cancers in the recent years. Determination of the status of immune checkpoint expression in particular cancers may assist decision making. Here, we describe the development of a single-stranded aptamer-based molecular probe specifically recognizing human PD-L1. Target engaging aptamers are selected by iterative enrichment from a random ssDNA pool and the binding is characterized biochemically. Specificity and dose dependence is demonstrated in vitro in the cell culture using human kidney tumor cells (786-0), human melanoma cells (WM115 and WM266.4) and human glioblastoma LN18 cancer cells. The utility of the probe in vivo is demonstrated using two mouse tumor models, where we show that the probe exhibits excellent potential in imaging. We postulate that further development of the probe may allow universal imaging of different types of tumors depending on their PD-L1 status, which may find utility in cancer diagnosis.
Insights
Researchers developed a novel aptamer probe to detect PD-L1, a key target in cancer immunotherapy. This probe shows promise for imaging tumors based on their PD-L1 expression, aiding cancer diagnosis.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Research
Background:
- Immune checkpoint inhibitors have transformed cancer treatment.
- Assessing immune checkpoint expression is crucial for treatment decisions.
- PD-L1 is a significant target in cancer immunotherapy.
Purpose of the Study:
- To develop a molecular probe for specifically detecting human PD-L1.
- To evaluate the probe's utility in vitro and in vivo for cancer imaging.
Main Methods:
- Selection of aptamers via iterative enrichment from a random ssDNA pool.
- Biochemical characterization of aptamer binding.
- In vitro specificity and dose-dependence testing using human cancer cell lines.
- In vivo imaging studies in mouse tumor models.
Main Results:
- A single-stranded aptamer-based molecular probe specifically recognizing human PD-L1 was successfully developed.
- The probe demonstrated specificity and dose-dependent binding in vitro across kidney, melanoma, and glioblastoma cell lines.
- In vivo studies in mouse models indicated the probe's excellent potential for tumor imaging.
Conclusions:
- The developed aptamer probe is a promising tool for PD-L1 detection.
- This probe has potential applications in cancer diagnosis and imaging based on PD-L1 status.
- Further development could lead to universal tumor imaging across various cancer types.
More Related Videos
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017